Molecular Genetics and Metabolism Reports (Jun 2020)

Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America

  • Martha L. Solano,
  • Alejandro Fainboim,
  • Juan Politei,
  • Gloria L. Porras-Hurtado,
  • Ana Maria Martins,
  • Carolina F. Moura Souza,
  • Felipe Mendez Koch,
  • Hernan Amartino,
  • Jose Maria Satizábal,
  • Dafne D.G. Horovitz,
  • Paula F.V. Medeiros,
  • Rachel S. Honjo,
  • Charles M. Lourenço

Journal volume & issue
Vol. 23

Abstract

Read online

Background: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders, leading to the progressive accumulation of glycosaminoglycans (GAGs) and the subsequent compromising of tissues and organ malfunction. Although incurable, most types of MPS can be treated with enzyme replacement therapy (ERT), an approach that has had positive effects on the natural clinical evolution and which impact has been extensively investigated. Unfortunately, to date, there is relatively little data regarding the effects of ERT interruption, especially in Latin America, where such interruption may be frequent due to a variety of issues (for instance, difficulties involving logistics, reimbursement and/or payment withdrawal). Method: A group of medical professionals from Latin America with experience in Genetics, Pediatrics and Neurology held an Advisory Board Meeting in the city of São Paulo, in October 2018, to discuss the issue of ERT interruptions in the region and recommendations to health care professionals on how to deal with these interruptions and better assess the therapeutic effects of ERT. Conclusion: Recommendations provided by the experts may support physicians in dealing with the most common reasons for ERT interruptions in Latin America. Most importantly, recommendations for data collection at specific timepoints (at baseline, throughout the treatment and during the interruption period of ERT and after its resumption) can significantly improve the collection of real world evidence on the effects of ERT and its interruptions, supporting health care professionals and policy makers in the decision making regarding the provision of these therapies for MPS patients.

Keywords